Those who are looking into the action in the premarket trading period would probably have noticed that the stock of the biopharmaceutical company Aptinyx Inc (NASDAQ:APTX) has fallen by 6%.to $3.30.
The price action in the stock must have been triggered by the company’s announcement yesterday about the fact that it has completed the design for the Phase 2 study of its product NYX 783. The product is meant for patients who suffer from post traumatic shock disorder.
The announcement was made by Aptinyx after it got the minutes of its meeting with the United States Food and Drug Administration. The Phase 2 study is expected to comment at some point in the fourth quarter of 2021.
However, it is also necessary to point out that the company also announced that it had identified a statistical error that was by the contract research organisation. It is now going to be interesting to see if the stock can actually make a recovery later on today.
Moving Averages
| +/- EMA(20) | 2.91 (+19.93%) |
| +/- SMA(50) | 2.73 (+27.84%) |
| +/- SMA(200) | 3.30 (+5.76%) |
| Pivot Points | |||||||
| Name | S3 | S2 | S1 | Pivot Points | R1 | R2 | R3 |
| Classic | 2.7867 | 2.9833 | 3.2367 | 3.4333 | 3.6867 | 3.8833 | 4.1367 |
| Fibonacci | 2.9833 | 3.1552 | 3.2614 | 3.4333 | 3.6052 | 3.7114 | 3.8833 |
 Stock Falls){kind=link}